Alnylam Pharmaceuticals, Inc.

DB:DUL Stock Report

Market Cap: €29.6b

Alnylam Pharmaceuticals Valuation

Is DUL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DUL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DUL (€225.9) is trading below our estimate of fair value (€810.43)

Significantly Below Fair Value: DUL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DUL?

Key metric: As DUL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DUL. This is calculated by dividing DUL's market cap by their current revenue.
What is DUL's PS Ratio?
PS Ratio14.4x
SalesUS$2.09b
Market CapUS$30.35b

Price to Sales Ratio vs Peers

How does DUL's PS Ratio compare to its peers?

The above table shows the PS ratio for DUL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.2x
BIO3 Biotest
1.5x3.6%€1.4b
FYB Formycon
15.9x24.6%€965.8m
BAYN Bayer
0.4x1.0%€19.0b
MRK Merck KGaA
2.9x4.2%€61.0b
DUL Alnylam Pharmaceuticals
14.4x21.2%€30.4b

Price-To-Sales vs Peers: DUL is expensive based on its Price-To-Sales Ratio (14.4x) compared to the peer average (5.2x).

Price to Sales Ratio vs Industry

How does DUL's PS Ratio compare vs other companies in the DE Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
DUL 14.4xIndustry Avg. 8.3xNo. of Companies5PS0612182430+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: DUL is expensive based on its Price-To-Sales Ratio (14.4x) compared to the European Biotechs industry average (8.2x).

Price to Sales Ratio vs Fair Ratio

What is DUL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DUL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.4x
Fair PS Ratio10.6x

Price-To-Sales vs Fair Ratio: DUL is expensive based on its Price-To-Sales Ratio (14.4x) compared to the estimated Fair Price-To-Sales Ratio (10.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DUL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€225.90
€285.20
+26.2%
17.1%€381.40€169.72n/a30
Dec ’25€239.10
€283.09
+18.4%
17.2%€379.00€168.66n/a30
Nov ’25€249.90
€278.06
+11.3%
16.7%€369.12€166.10n/a29
Oct ’25€245.00
€256.12
+4.5%
19.6%€358.32€143.78n/a28
Sep ’25€205.90
€253.29
+23.0%
19.5%€358.36€143.79n/a27
Aug ’25€222.10
€249.99
+12.6%
19.5%€370.68€148.74n/a27
Jul ’25€224.50
€231.94
+3.3%
21.9%€373.40€140.03n/a27
Jun ’25€137.65
€204.89
+48.8%
23.1%€371.88€128.30n/a26
May ’25€136.65
€205.52
+50.4%
23.1%€369.25€127.13n/a27
Apr ’25€141.80
€202.64
+42.9%
23.3%€362.81€124.92n/a26
Mar ’25€139.00
€202.98
+46.0%
22.9%€365.02€125.68n/a26
Feb ’25€159.20
€208.03
+30.7%
20.7%€363.40€132.48n/a26
Jan ’25€175.80
€205.90
+17.1%
21.6%€362.33€123.84€225.8026
Dec ’24€153.40
€205.88
+34.2%
21.6%€362.93€124.04€239.1026
Nov ’24€148.00
€212.99
+43.9%
21.8%€373.24€118.11€249.9026
Oct ’24€164.00
€230.67
+40.7%
18.9%€383.45€126.87€245.0026
Sep ’24€181.40
€221.79
+22.3%
18.9%€368.02€128.13€205.9025
Aug ’24€176.40
€221.58
+25.6%
18.7%€365.07€126.20€222.1025
Jul ’24€174.60
€228.78
+31.0%
19.4%€383.29€125.61€224.5025
Jun ’24€172.20
€228.37
+32.6%
19.6%€385.70€126.40€137.6526
May ’24€176.60
€224.32
+27.0%
20.7%€376.61€123.42€136.6525
Apr ’24€177.72
€227.70
+28.1%
20.8%€382.59€125.38€141.8025
Mar ’24€179.46
€234.01
+30.4%
20.8%€393.38€128.91€139.0025
Feb ’24€206.20
€227.60
+10.4%
20.4%€381.92€131.60€159.2024
Jan ’24€221.35
€226.83
+2.5%
21.0%€391.51€136.79€175.8024

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 07:35
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alnylam Pharmaceuticals, Inc. is covered by 65 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
Emily BodnarBerenberg